Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: A multi-center, phase 3, randomized, controlled clinical trial.
Wei Wei(Zhujiang Hospital), Rongping Guo(Sun Yat-sen University), Chong Zhong(Guangzhou University of Chinese Medicine), Jian‐Hong Zhong(Tumor Hospital of Guangxi Medical University), Rui Luo(First Affiliated Hospital of Guangzhou University of Chinese Medicine), Lie Zheng(Sun Yat-sen University), Mingrong Cao(First Affiliated Hospital of Jinan University), Bang‐De Xiang(Ministry of Education of the People's Republic of China), Changzhen Shang(Sun Yat-sen University), Yuchuan Jiang(First Affiliated Hospital of Jinan University), Shaohua Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Qiang Li(Central South University), Rongce Zhao(Sun Yat-sen University), Yuan Cheng(Zhujiang Hospital), Lianghe Lu(Sun Yat-sen University), Jie Mei(Sun Yat-sen University), Qiucheng Lei(Foshan Hospital of TCM), Jibin Li(State Key Laboratory of Pollution Control and Resource Reuse), Huanwei Chen(Changhua Christian Hospital), Mingxin Pan(Zhujiang Hospital)
Cited by 13
Related Papers
Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection
|Journal of Hepatology|2018|559
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216